Jacobio Pharmaceuticals Group (1167) H1 2026 earnings summary

Executive summary

• Achieved significant revenue growth and turned profitable, driven by major licensing deals and clinical progress.

• Advanced multiple oncology drug candidates, including KRAS inhibitors and ADC platforms, with several clinical and regulatory milestones.

• Strengthened global partnerships, notably with AstraZeneca and Allist, to expand R&D and commercialization.

• Announced senior management changes and continued focus on pipeline innovation and global expansion.

Financial highlights

• Revenue rose 1499.3% year-over-year to RMB730.9 million for H1 2026, mainly from AstraZeneca and Allist collaborations.

• Gross profit increased to RMB712.7 million from RMB45.7 million year-over-year.

• Net profit reached RMB600.6 million, reversing a net loss of RMB59.0 million in H1 2025.

• R&D expenses slightly decreased to RMB92.2 million, with administrative expenses stable at RMB18.6 million.

• Adjusted profit for the period was RMB602.7 million, excluding share-based payments and fair value changes.

• Cash and bank balances rose to RMB1,680.1 million as of June 30, 2026.

Outlook and guidance

• Plans to further develop and commercialize KRAS and iADC pipelines, targeting global leadership in oncology.

• Focus on expanding partnerships, advancing allosteric inhibitor and iADC platforms, and pursuing global market opportunities.

• No interim dividend declared for H1 2026.